Innate Pharma (IPHYF) Equity Ratio (2017 - 2019)

Innate Pharma's Equity Ratio history spans 3 years, with the latest figure at 0.54 for Q4 2019.

  • For Q4 2019, Equity Ratio rose 46.15% year-over-year to 0.54; the TTM value through Dec 2019 reached 0.54, up 46.15%, while the annual FY2019 figure was 0.54, 46.15% up from the prior year.
  • Equity Ratio reached 0.54 in Q4 2019 per IPHYF's latest filing, up from 0.37 in the prior quarter.
  • In the past five years, Equity Ratio ranged from a high of 0.54 in Q4 2019 to a low of 0.34 in Q4 2017.
  • Average Equity Ratio over 3 years is 0.42, with a median of 0.37 recorded in 2018.
  • Peak YoY movement for Equity Ratio: increased 9.97% in 2018, then surged 46.15% in 2019.
  • A 3-year view of Equity Ratio shows it stood at 0.34 in 2017, then increased by 9.97% to 0.37 in 2018, then skyrocketed by 46.15% to 0.54 in 2019.
  • Per Business Quant, the three most recent readings for IPHYF's Equity Ratio are 0.54 (Q4 2019), 0.37 (Q4 2018), and 0.34 (Q4 2017).